title: Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers.
abstract: BACKGROUND
  Prucalopride (PR) is a novel 5-HT4 agonist enterokinetic compound.
  
  
  OBJECTIVE
  To evaluate its effect on bowel function, gut transit and anorectal function in healthy volunteers using a double-blind, placebo-controlled crossover study.
  
  
  METHODS
  Twenty-four healthy volunteers (12 men, 12 women, mean age 25 years, range 20-53 years) were randomly assigned to 1 mg/placebo or 2 mg/placebo (PL). The trial consisted of five consecutive 1 week periods: no drug treatment, PR treatment or PL, washout, PL or PR, no treatment. Subjects maintained a diary of bowel function during the entire study period. Total intestinal transit time (TITT), mean colonic transit time (MCTT) and anorectal function (anal manometry, rectal sensitivity and rectal compliance) were assessed at the end of both treatment periods. Electrocardiography and blood sampling were performed for safety analysis; blood sampling was also used to check compliance.
  
  
  RESULTS
  No subjects withdrew from the study. Treatment with PR 2 mg showed a statistically significant increase in mean number of weekly stools (11.5 vs. 7.1 compared to PL, P = 0.04) and in the percentage of loose/watery stools (48 vs. 12% compared to PL, P = 0.005). Within 1 week, stool frequency and consistency returned to baseline values when treatment was stopped. MCTT was shortened significantly with both doses, i.e. from 35 h on PL to 25 h on PR 1 mg (P = 0.01) and from 43 h on PL to 22 h on PR 2 mg (P = 0.02). Anorectal function was unaffected by PR. Transient and moderate headache occurred in nine subjects during PR treatment and in six subjects during PL treatment.
  
  
  CONCLUSIONS
  Prucalopride is well tolerated by healthy subjects and has a marked and consistent effect on stool frequency and consistency, and on colonic transit. In the present study prucalopride did not affect visceral sensitivity or sphincter function. It holds promise for patients with slow transit constipation.
authors.affiliation: Department of Gastroenterology, Academic Hospital 'Vrije Universiteit', Amsterdam, The Netherlands.
authors.forename: A C
authors.initials: AC
authors.lastname: Poen
authors.forename: R J
authors.initials: RJ
authors.lastname: Felt-Bersma
authors.forename: P A
authors.initials: PA
authors.lastname: Van Dongen
authors.forename: S G
authors.initials: SG
authors.lastname: Meuwissen
mesh_terms: D000328:Adult; D001003:Anal Canal / Q000187:drug effects*; D001572:Benzofurans / Q000009:adverse effects / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects; D018592:Cross-Over Studies; D003672:Defecation / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology*; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012007:Rectum / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D001572:Benzofurans; D005765:Gastrointestinal Agents; D012702:Serotonin Antagonists; C406662:prucalopride